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Abstract: In the present study, we evaluated and described the
sensitivity of the stem cell marker B cell-specific moloney murine
leukemia virus integration site 1 (Bmi-1) in identifying early lesions of
carcinoma ex pleomorphic adenoma (CXPA). While invasive CXPAs
are tumors with a prominent and easily recognizable malignant com-
ponent, the identification of early carcinomatous changes in PA remains
a diagnostic challenge due to the lack of objective morphological
criteria. The immunohistochemical expression of Bmi-1 was assessed
in both adenomatous and carcinomatous components of 9 CXPA cases
at an early phase of histological progression (6 intracapsular and 3
minimally invasive) grouped according to the cellular differentiation as
luminal (7 cases) or myoepithelial (2 cases). A selective nuclear
expression of Bmi-1 was found exclusively in the malignant component
of 8 cases (6 luminal type and 2 myoepithelial type), including
intraductal carcinoma areas, except for 1 case in which scarce cells
of the remnant PA were positive. Thus, Bmi-1 is expressed from the
earliest morphologically detectable stages of PA malignant transform-
ation. When faced with atypical features in PA, evaluation of Bmi-1
expression can provide more objective criteria for identification and
diagnosis of early lesions of CXPA. This is applied to carcinomas with
luminal or myoepithelial differentiation.
(Medicine 94(27):e1035)
Abbreviations: a-SMA = a-smooth-muscle actin, AJCC =
American Joint Committee on Cancer, Bmi-1 = B cell-specific
moloney murine leukemia virus integration site 1, CK =2/neu = human epidermal growth factor receptor-type 2, PA =mani, PhD, Fa´bio s, PhD,
ousa, PhD
INTRODUCTION
C arcinoma ex pleomorphic adenoma (CXPA) is defined asan epithelial malignancy that develops in association with a
primary or recurrent pleomorphic adenoma (PA), the most
common salivary gland tumor, and constitutes about 3.5% of all
salivary gland neoplasms.1,2 Most cases affect the parotid glands,
but it canoccur in any sitewherePAoccurs,mainly inpatients aged
between the 6th and 7th decades of life.2 The pathogenesis of
CXPA is poorly understood and has been linked to the accumu-
lation of genetic disturbances in long-standing PAs.1,2
Under microscopic examination, the diagnostic criteria for
identification of carcinomatous areas in PA have not been fully
established and are subjective. Besides this, PA may display
cellular abnormalities or even intravascular tumor deposits,
mainly after diagnostic procedures, and these findings alone
are not sufficient for the diagnosis of malignancy.3 Extensive
stromal hyalinization, hypercellularity, frank cellular atypia,
increased mitotic activity, necrosis, and capsular infiltration are
commonly associated to malignant transformation in PA,
although on histopathological examination alone it is some-
times difficult to distinguish ‘‘innocent’’ atypical features from
true CXPA, especially early lesions.1,2,4,5
Recent evidences have shown the existence of subpopu-
lations of neoplastic cells capable to maintain tumor growth and
heterogeneity by its peculiar capacity of self-renewal.6 The so-
called cancer stem cells were firstly described in acute leukemia
but have been identified in solid tumors.7–9 Besides, cancer
stem cells seem to be closely involved in tumor initiation and
progression, as well as resistance to conventional chemother-
apeutic and radiotherapeutic treatments.10
The expression of several markers has been associated
with stem-cell-like properties in neoplastic cells. The B cell-
specific moloney murine leukemia virus integration site 1 (Bmi-
1) is a transcriptional receptor of the polycomb gene family
involved in several cellular processes including cell-cycle
regulation, apoptosis, and maintenance of adult and neoplastic
stem cells by providing self-renewal capacity.11,12 Further,
Bmi-1 expression has been associated with malignant trans-
formation, tumor progression, metastatic disease, and poor
prognosis in human malignancies.13–16 Therefore, we aimed
to describe and evaluate the sensitivity of Bmi-1 expression as a
diagnostic marker for malignant change in a case series of
CXPA at an early phase of carcinomatous progression.
MATERIALS AND METHODS
Patients and Tissue Samples
This study was approved by the local Ethics Committee.f the head and neck region at an early
us progression (early CXPAs) were
s of Anatomical Pathology Diagnostic
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TABLE 1. Details of the Primary Antibodies
Antibody Clone Immunohistochemical Dilution Antigenic Retrieval Incubation (h)
Bmi-1 D20B7 1:300 Citrate 18
CK7 OV-TL12130 1:50 Citrate 1
CK14 LL02/1 1:500 Citrate 1
a-SMA 1A4 1:200 Citrate 1
Vimentin Vim 3B4 1:800 Citrate 1
Sedassari et al Medicine  Volume 94, Number 27, July 2015Service at the School of Dentistry of the University of Sa˜o Paulo
and of the Department of Anatomic Pathology at the School of
Medicine of the State University of Campinas. Were considered
as early CXPAs those cases in which the carcinoma was
confined to the PA capsular boundaries (intracapsular) or with
up to 1.5mm of extracapsular infiltration (minimally invasive),
according to the World Health Organization classification sys-
tem.1 All diagnosis were reviewed and confirmed by 3 pathol-
ogists (A.A., B.T.S., and S.S.) using slides routinely stained in
hematoxylin and eosin. Cases were also subdivided according to
cellular component of the carcinomatous areas into 2 groups:
early CXPAs with luminal differentiation and early CXPAs with
myoepithelial differentiation. Clinical information was
obtained from the patient’s medical records and cases were
staged according to the American Joint Committee on Cancer
(AJCC).17
Immunohistochemistry
One representative paraffin block was chosen for immu-
nohistochemical examination and the anti-Bmi-1 antibody was
used. In order to accurately classify the carcinomas according
to the cellular differentiation (ie, luminal/epithelial or ablum-
inal/myoepithelial) and to identify areas of intraductal carci-
noma, the following antibodies were used: cytokeratins 7
(CK7) and 14 (CK14), a-smooth-muscle actin (a-SMA),
vimentin, and p63. The details of the antibodies used are
summarized in Table 1.
Briefly, sections of 3-mm thickness were obtained from
formalin-fixed and paraffin-embedded tissues. Dewaxed sec-
tions were subjected to antigen retrieval for 30minutes by
boiling in a steamer at 958C (citrate pH 6.0 or Tris–EDTA
pH 9.0). Endogenous peroxidase was quenched by incubation
with 3% hydrogen peroxide and methanol. Sections were
incubated with primary antibody and then with EnVision poly-
mer (DakoCytomation, Carpinteria, CA) for 1 hour, followed by
staining with 3,30-diaminobenzidine tetrahydrochloride (DAB)
and then counterstaining with Mayer’s hematoxylin. Appropri-
ate positive controls were used in all immunohistochemical
reactions. Negative control was obtained by omitting the
primary antibody.
Immunostaining Evaluation
The labeled sections were evaluated by 2 observers without
knowledge of patient’s clinicopathological data. Immunoex-
pression of CK7, CK14, a-SMA, vimentin, and p63 was
classified qualitatively as positive or negative. For Bmi-1
p63 4A4 1:400
a-SMA¼a-smooth muscle actin; CK¼ cytokeratin.expression, the percentage of tumor cells was assessed semi-
quantitatively in both adenomatous and carcinomatous areas,
according to the following previously described score system18:
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CoTris–EDTA 1(1) Score 0—no positive cell;(2) Score 1—up to 30% of positive cells;(3) Score 2—30–50% of positive cells;
(4) Score 3—50–80% of positive cells;
(5) Score 4—over 80% of positive cells.
RESULTS
Clinical Data
The studied group of patients consisted of 5 women and 4
men with mean age of 56 years (range 41–74). The most
common localization was the parotid gland, followed by
intraoral salivary glands and lacrimal gland. All cases consisted
of T1, T2, or T3 tumors without nodal or distant metastasis at the
time of diagnosis and treated by surgical excision. No patient
received adjuvant therapy.
Residual Pleomorphic Adenoma
Residual PA areas consisted of occasional double-layered
ductiform structures associated with cords and islands of
epithelioid to plasmacytoid myoepithelial cells embedded in
amyxochondroid stroma, oftenwith hyalinization (Figure 1A).
There was no cellular pleomorphism. Luminal cells expressed
CK7 and the modified myoepithelial component strongly
stained to CK14, vimentin, p63, and focally to a-SMA. In
only 1 luminal-type CXPA case, scarce cells in residual PA
were positive to Bmi-1 (Figure 1B).
Early CXPAs With Luminal Differentiation
This group was composed by 5 intracapsular and 2 mini-
mally invasive CXPAs. In such cases, the neoplastic cells were
strongly positive to CK7 and focally to CK14, lacking any
staining against myoepithelial markers. Intraductal carcinoma
(transitional) areas were present in 6 cases and were charac-
terized by duct-like structures expanded by transformed luminal
cells with marked pleomorphism and associated with central
necrosis, positive to CK7 and focally to CK14. Those structures
were externally bounded by a rim of benign oval to spindled
compressed myoepithelial cells positive to CK14, a-SMA,
vimentin, and p63 (Figure 1C). In these areas, the atypical
luminal cells diffusely expressed Bmi-1 (Figure 1D). In fre-
quent regions, the reminiscent myoepithelial layer was not
evident characterizing invasion of the carcinomatous com-
ponent into the PA stroma, but still respecting the PA capsule
(Figure 2A). Such areas were hypercellular with numerousular ductiform spaces lined by large and pleomorphic cells,
similar immunoprofile to luminal cells in intraductal areas,
cing PA structures (Figure 2B). In 2 cases, the carcinoma
pyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. (A) Occasional double-layered ductiform structures and cords of modified myoepithelial cells in a myxoid stroma compose
residual pleomorphic adenoma areas. No cellular pleomorphism is present (hematoxylin and eosin (H&E), original magnification 400).
(B) Scarce Bmi-1-positive cells in remnant pleomorphic adenoma areas (original magnification, 400). (C) Intraductal carcinoma area
characterized by expanded ductiform structures lined by highly pleomorphic transformed ductal cells, occasionally with individual
necrotic cells, externally bounded by a rim of bland-looking myoepithelial cells (arrows) (H&E, original magnification, 400). (D) Bmi-1
expression in luminal transformed cells (original magnification, 400).
FIGURE 2. Intracapsular luminal-type carcinoma ex pleomorphic adenoma with extraductal component. (A) Numerous irregular duct-
like structures replacing the ‘‘maternal’’ pleomorphic adenoma (myxoid area), but respecting the capsule (hematoxylin and eosin (H&E),
original magnification 100). (B) In a high-power view, juxtaposed duct-like structures lined by pleomorphic cells (H&E, original
magnification 400). (C) Nuclear Bmi-1 expression in carcinomatous cells (original magnification, 400).
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FIGURE 3. Intracapsular myoepithelial-type carcinoma ex pleomorphic adenoma. (A) Blocks of clear to eosinophilic cells pushing the
capsule. A neoplastic islet is infiltrating the capsular connective tissue (arrows) (hematoxylin and eosin (H&E), original magnification,
act
nu
Sedassari et al Medicine  Volume 94, Number 27, July 2015penetrated into the extracapsular tissues in up to 1.5mm (mini-
mally invasive CXPAs). Similar to intraductal carcinoma areas,
the extraductal carcinomatous component exhibited positive
nuclear expression against Bmi-1 while residual PA areas were
negative, except for 1 case (Figure 2C).
Early CXPAs With Myoepithelial Differentiation
One intracapsular and 1 minimally invasive CXPA com-
posed this group. In both cases, intraductal carcinoma areas
were not identified and the transition from the adenoma to
carcinoma was abrupt. The carcinomatous component was
characterized by invasive solid blocks composed predominantly
by clear to plasmacytoid cells in a hyalinized and hemorrhagic
background with occasional foci of coagulative necrosis
(Figure 3A). Those cells lacked pleomorphism, brisk mitotic
activity, or ductal formation (Figure 3B) and were strongly
positive to CK14, vimentin, p63 and focally to a-SMA. The 2
cases displayed a diffuse and selective expression of Bmi-1 in
the carcinomatous component (Figure 3C).
All clinicopathological and immunohistochemical results
are summarized in Table 2. Statistical analysis was not per-
formed due to the small number of cases and marked differences
between benign and malignant areas seen in all cases.
DISCUSSION
In the present study, we have demonstrated Bmi-1 protein,
a stem cell marker, as a helpful tool in identifying areas of
malignant transformation in PA. CXPA is an uncommon tumor,
100). (B) In detail, myoepithelial carcinoma composed by comp
mitotic activity (H&E, original magnification, 400). (C). Diffuse
magnification, 400).representing the 6th most common malignancy of the salivary
glands according to Armed Forces Institute of Pathology data.2
The real incidence of malignization in PA is difficult to
4 | www.md-journal.comestimate, but it seems to be inwardly associated with accumu-
lation of genetic disturbances in long-standing tumors, occur-
ring in about 6.2% of patients with PA.1,2,19 The risk of
malignant transformation increases from 1.6% for PAs with
clinical duration of 5 years or less to 9.5% in cases with over
than 15 years of duration.2
In its natural history of tumor progression, CXPA develops
within the confines of the parent PA and invades beyond the
capsule with time. Irrespective of the histological subtype,
CXPA can be subclassified into 2 main prognostically related
groups regarding the capsular invasion: invasive and noninva-
sive/early CXPAs.20 The former are the most common histo-
logical subtype of CXPA, often associated with metastatic
disease and poor prognosis.1,2 In such cases, the histological
malignant component is usually evident and easily recogniz-
able.1,2,20 On the other hand, early CXPAs, the least common
form of CXPA which justifies the limited number of cases here
studied, generally have good prognosis but its diagnosis remains
a challenge once the morphologic criteria for detecting early
lesions of CXPA have not been fully established.21 Despite its
benign clinical behavior, these tumors are malignancies not
completely devoid of metastatic potential.22 Thus, recognition
of at least small foci of malignant transformation in PA has
clinical relevance since patients need to be carefully monitored.
No patient here presented had metastatic disease at the time of
diagnosis or was diagnosed at an advanced clinical stage,
reaffirming the favorable clinical behavior of early CXPA.
Both luminal and myoepithelial components of PA may
undergo malignant transformation and the carcinoma seems to
nests of clear cells lacking pleomorphism, ductal formation, and
clear Bmi-1 expression in malignant myoepithelial cells (originalarise from the former in most cases.23 Morphological evidence
that support this theory is the identification in some CXPA cases
of the so-called intraductal/transitional carcinoma areas,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.characterized by ductal structures expanded by pleomorphic
transformed luminal cells confined by a rim of bland-looking
benign myoepithelial cells.2,20,23 The identification of Bmi-1
expression in such areas of our luminal-type cases seems to
indicate that this is probably an early event in malignant trans-
formation of PA. Bmi-1 is a key epigenetic regulator that
mediates gene silencing by regulating chromatin structure and
it is known to enhance self-renewal in cancer stem cells.12,24 The
selective expression of Bmi-1 in transformed cells of CXPA also
suggests the acquisition of stem cell-like properties by these cells.
These characteristicsmay contribute to the biological advantages
necessary for tumor progression and invasion. Furthermore,Bmi-
1 expression has been associated with malignant transformation
and tumor progression in carcinomas of the upper aerodigestive
tract, prostate, lung, and stomach.7,13,14,16,25,26
With the intent to minimize subjectivity in evaluating the
presence of early carcinomatous changes in PA, some bio-
markers have been demonstrated as helpful tools in distinguish-
ing innocent atypical features from true CXPA lesions. Besides
Bmi-1, other immunohistochemical markers can help in iden-
tifying malignant change in PA. Membranous expression of
human epidermal growth factor receptor-type 2 (HER-2/neu) or
its amplification by fluorescent in situ hybridization has been
exclusively associated with luminal-type malignant trans-
formed cells in CXPA, even in noninvasive cases, as well as
a high proliferative index of Ki-67 or less reliably p53 expres-
sion.27–29 Still, HER-2/neu does not seem to be sensitive in
identifying CXPA cases with myoepithelial differentiation or
those cases with low-grade histology.27
It is estimated that 50% of myoepithelial carcinomas arise
in association with previous PA.30 Further, these tumors use to
lack cellular pleomorphism and identification of an invasive
growth is mandatory for the diagnosis of malignancy.2,30 This
fact makes the recognition of myoepithelial-type CXPAs more
difficult when compared to those cases with luminal phenotype
due to the fact that the contrast between the malignant myoe-
pithelial component and the PA is less evident. Added to this,
PA may emit ‘‘pseudopods’’ to the capsule and cases of the
intraoral region commonly are cellular with an exuberant
myoepithelial component and ill-defined limits due to the
incomplete or even lack of encapsulation.2,3,31 These
peculiarities may raise suspicion for malignancy in some cases.
Interestingly, the 2 cases of myoepithelial-type CXPAs here
presented showed a diffuse and selective Bmi-1 expression in
malignant myoepithelial cells. Despite the small number of
cases, our data indicate that Bmi-1 may be a useful marker to
recognize myoepithelial carcinoma associated with PA, even in
intracapsular cases or those in early phases of invasion.
In 1 intracapsular CXPA case of our series, the PA
component displayed a slight positivity to Bmi-1. Such areas
were devoid of cellular pleomorphism on histopathological
examination, but were closely associated with carcinomatous
foci. This finding could be partially explained by the fact that
Bmi-1 is part of a protein complex and it may be involved in
tumorigenesis of either, benign and malignant tumors. Besides,
morphology is the final product of multiple genetic and environ-
mental events in association and those positive cells in residual
PA areas may display an intrinsic genotype associated with
malignant transformation but, at that time, still not translated
into a carcinomatous phenotype. Cases in which Bmi-1 expres-
sion is inconclusive, an accurate correlation of clinical history
BMI-1 in Early Carcinoma ex Pleomorphic Adenomaand morphological aspects is crucial to the definitive diagnosis.
Knowledge of previous diagnostic manipulation is helpful for
the evaluation of atypical features in PA. Fine needle aspiration
www.md-journal.com | 5
cytology, incisional biopsies or trauma may result in necrosis,
extensive hemorrhage and mucosal ulceration often associated
with reactive cytologic atypia, metaplastic elements, epithelial
proliferation, or even intravascular tumor deposits.2,3,32 Such
areas use to be focal and isolated by fibrosis and inflammation.2
On the other hand, histological findings of frank cytologic
atypia with mitotic activity, including atypical forms, necrosis
of individual cells or in foci, extensive stromal hyalinization and
capsular violation are highly indicative of malignant change
instead of a reactive process, mainly in the absence of clinical
information that support these findings.
Thus, in conclusion, PA without malignant transformation
may share overlapping morphological aspects with early lesions
of CXPA, making microscopic distinction a challenge even for
experienced pathologists. Added to this, the histopathological
finding of cellular atypia alone is not sufficient to define
malignant transformation in PA. The selective Bmi-1 expres-
sion from the earliest morphologically identifiable stages of
CXPA indicates that this protein is important to the process of
PA malignant transformation. Ultimately, in a clinicopatholo-
gical context, Bmi-1 expression can provide more objective
criteria, alone or associated with other markers, to distinguish
atypical features in PA from true lesions of CXPA. This is
applied to CXPAs with luminal or myoepithelial differentiation.
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